$EBS

Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.

Novavax (NVAX) shares surged 20% after a suspected plague death in Russia sparked investor interest in vaccine stocks. Moderna (MRNA) rose 7.1% and Emergent BioSolutions (EBS) gained 15.3%. The rally is attributed to short covering and sentiment, not new revenue prospects. NVAX's short interest is 30.43% of its float, setting up a potential squeeze.

Emergent Biosolutions (EBS) stock rose 19.6% to $7.57 after a suspected pneumonic plague death in Russia. The company's biodefense portfolio and strong Q2 earnings, with adjusted EPS of $0.60 and revenue of $234.3M, supported the surge. Analysts have a consensus 'Hold' rating with a $10.00 price target. The broader market also gained, with the S&P 500 up 0.7% and Nasdaq up 1.0%.

Emergent BioSolutions (EBS) received a $24M contract modification from BARDA for its CYFENDUS anthrax vaccine, supporting national preparedness. The FDA-approved vaccine is used for post-exposure prophylaxis. EBS stock is up 0.82% at $6.15.

S&P Global Ratings revised Emergent BioSolutions' outlook to negative, citing lower revenue guidance due to competition in the naloxone market. The company reduced its 2026 revenue and EBITDA guidance by $80M and $25M, respectively, due to weaker NARCAN sales. S&P noted potential refinancing risks for Emergent's $440M unsecured notes maturing in 2028, with declining revenue and uncertain growth prospects.

Emergent BioSolutions (EBS) reported Q2 updates on its MCM and naloxone franchises. Management said MCM international sales were about 20% of first-half 2026 revenue. It received regulators’ approvals to expand ACAM2000 to Mpox. Due to NARCAN competition, EBS lowered 2026 revenue guidance to $645M-$675M and recorded a ~$191M non-cash impairment, plus ~$40M annualized cost savings.

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Emergent BioSolutions (EBS) reported Q2 2026 revenue of $234.3 million, up 66% year over year, driven by accelerated U.S. government MCM contract modifications. Net loss widened to $180.2 million due to a $191.3 million non-cash Naloxone impairment. Adjusted EBITDA rose to $96.5 million. The company cut 2026 guidance and announced restructuring, including wet lab closures and about 93 job reductions.

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS • Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year • Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. ebs-20260626 0001367644 false 0001367644 2026-06-26 2026-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):